Treatment landscape for EGFR #lungcancer is getting more complex - for clinicians & patients. But as Dr Jurgen Wolf says at #ESMO24 “Always good to have several arrows in your quiver.” Absolutely agree. Stratifying which patients are best for which option is key Jurgen Wolf

🌟And here with the efficacy and safety data of #NVL655, ALK-selective, TRK-sparing and brain-penetrant 4G ALK TKI, from ALKOVE-1, presented today #ESMO24 by Alexander Drilon MD ✅ ORR 38% in heavily pretreated pts overall (1-5 prior ALK TKIs) ✅ ORR 35% in pts post-lorlatinib (in which

Responses were durable, also with CNS activity including post-progression on lorlatinib, and importantly, favorable safety and tolerability overall c/w ALK selective design 📢 Phase II study ALKOVE-1 is ongoing, evaluating NVL-655 in pts who are TKI-naive AND TKI-pretreated

Low dose versus standard dose pembrolizumab for treatment of stage IV stage NSCLC: Results of the pre-planned interim analysis of the NVALT-30 clinical trial ❓Will this be the end of the discussion? Thoughts? #ESMO24 #LCSM

Wonderful to be at #ESMO24 with so many passionate, committed members of the lung cancer community. Fantastic research presentations and discussions. Together, we are so much stronger.

After adjuvant Alectinib for early stage ALK lung cancer, how to you handle progression? Can you re-challenge with Alectinib? Dr Ben Solomon answers these questions at #ESMO24 👇

Starting soon for those interested in learning more about local therapies for ALK+ stage IV NSCLC. ALK Positive Yvonne Diaz Oncogene Cancer Research alkpositivebelgium ALK+ International ALK Positive Australia Inc. @

Can inhaled corticosteroid reduce RT induced lung damage during radical lung rt for unresectable IIIa/b?; n292; yes it can. 15% reduction in radiation pneumonitis. #ESMO24 lovely trial; practice changing #ESMO24

Important data. Next step is to translate this into practice and policy. Unfortunately, surveillance brain MRI are still NOT routinely recommended in most society guidelines for early stage NSCLC, especially for #EGFR & #ALK. #LCSM Chat EGFR Resisters ALK Positive

We left #ESMO24 inspired by all the research presentations and fantastic community. See you in Berlin next year. #ResearchSavesLives #LCSM #hope

Great to be joining Drs Christian Rolfo Marina Garassino & Sanjay Popat at LUNGevity Foundation's International Lung Cancer Survivorship Conference taking place this weekend. Incredible agenda featuring many key opinion leaders & patient advocates. Join 👇reg.eventmobi.com/ilcsc24/regist… #ILCSC

Dr. Ken Culver, our Research & Clinical Affairs Director, spoke with Lung Cancers Today Today at #WCLC24 about how we're supporting research through our patient registry - the ALK Life Study. Ken also spoke about the importance of #biomarkertesting for all lung cancers. 📺👇 #LCSM

NVL-655: 4th-generation, #ALK-selective TKI w/ CNS penetration targeting diverse #ALK-mutant oncoproteins, including lorlatinib-resistant compound mutations. ✅>50-fold selectivity for ALK over 96% of the kinome tested & brain penetrant ✅≥100-fold⬆️ potency against ALK G1202R

Celebrating 20 yrs of progress in lung cancer is truly down to research bringing us improvements in treatments &s quality of life. Thanks Prof Solange Peters CHUV / Centre hospitalier universitaire vaudois for highlighting lots of research, including 23andMe Lung Cancer Genetics Study. 23andme.com/lung-cancer/?u…

Watch the replay of our recent ALKtALK w Drs Drew Moghanaki 🐕 & Matt Quirk - looking at the use of all forms of radiotherapy when tumors won't disappear. Lots of great topics covered the roles of ablation, radiotherapy & LCT for our ALK #lungcancer family. 📺youtu.be/5IhdEqbubzY?si…

Valuable information for anyone with an oncogene-driven lung cancer. We want to stay on our targeted therapies for as long as possible so looking at all the potential modalities of treatment including radiotherapy and ablation is part of a multidisciplinary approach. Check it out

Be sure to tune into @lungevity’s #ILCSC24 taking place all morning today from 9am ET. Our own President Kirk Smith will join an ALK+ lung cancer session at 1pm ET with the amazing Dr Jessica Lin. You can register at lungevity.org/ilcsc #lungcancer #survivor #hope

Great line up today @lungevity’s #ILCSC w many dedicated patient advocates & clinicians. Truly international & representative conf. Still time to register @ lungevity.org/ilcsc Our Co-founder Yvonne Diaz on at 9amET w Sanjay Popat Dr Marina Garassino & Christian Rolfo

ALK Positive ALK+ International ALKFusion LUNGevity Foundation LCRF

🫁 Renew & Final ‼️ 🫁 🫁 9 th edition TNM staging for Lung cancer 🫁 📌 The 9th edition TNM staging of lung cancer has been renewed and finalized. 📌 If you need the documents, please download the PDF from the link below. dropbox.com/scl/fi/pg0017g…